Investing.com··Chris MarkochBiogen Stock Tumbles on Diranersen Trial Miss, Yet Analysts Remain Optimistic
Biogen stock fell 10% after diranersen missed Alzheimer's trial primary endpoint, but analysts remain bullish on $215.62 price target given secondary efficacy signals and strong Leqembi growth.
BIIBESAIYphase 2 trialantisense oligonucleotide